Base de dados : HANSEN
Pesquisa : RIFAMICINAS/FARMACOL [Descritor de assunto]
Referências encontradas : 4 [refinar]
Mostrando: 1 .. 4   no formato [Detalhado]

página 1 de 1

  1 / 4 HANSEN  
              next record last record
seleciona
para imprimir
Id:18237
Autor:Pattyn, S. R; Saerens, E. J
Título:Activity of three new rifamycin derivates on the experimental infection by Mycobacterium leprae
..-
Fonte:s.l; s.n; 1977. 5 p. tab.
Resumo:Three new rifamycin derivates characterized by longer lasting were tested M. leprae in the mouse model. Their minimal effective dose is slightly to moderately lower than that of rifampicin. Intervals of administration can however not be increased over once every 2 weeks. On a weght basis one of the drugs is 8 times more potent than rifampicin.(AU).
Descritores:HANSENIASE/quimioter
RIFAMICINAS/farmacol
Limites:ESTUDO COMPARATIVO
ANIMAL
CAMUNDONGOS
Meio Eletrônico: - .
Localização:BR191.1; 01454/s


  2 / 4 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17921
Autor:Sanfilippo, A; Della Bruna, C; Marsili, L; Morvillo, E; Pasqualucci, C. R; Schioppacassi, G; Ungheri, D
Título:Biological activity of a new class of rifamycins. Spiro-piperidyl-rifamycins
..-
Fonte:s.l; s.n; Oct. 1980. 6 p. tab.
Resumo:The biological properties of spiro-piperidyl-rifamycins, a new class of rifamycin antibiotics, are described. In these derivatives the positions 3 and 4 have been incorporated into an imidazolyl ring bearing a spiro-piperidyl group N substituted with linear and branched aliphatic chains. The in vitro antibacterial activity against Staphylococcus aureus and Mycobacterium tuberculosis increases with the number of the carbon atoms in the linera side chain, whereas the inhibitory effect on Escherichia coli is lowered. The antibacterial activity is only marginally affected by branching of the side chain. In vivo (experimental infections of mice) the optimal therapeutic activity against M. tuberculosis is shown by compounds bearing 3 approximately 5 carbon atoms as a linear or branched side chain; in comparison with rifampicin, the potency of these derivatives is 2 approximately 3 times higher. The finding is in a good agreement with the exceptional tissue tropism, which seems to be a favourable property of this group of derivatives.
Descritores:CINETICA
RIFABUTINA
RIFAMICINAS/metab
RIFAMICINAS/farmacol
DISTRIBUICAO TECIDUAL
INFECCOES BACTERIANAS/quimioter
BACTERIAS/ef drogas
Limites:ANIMAL
FEMININO
CAMUNDONGOS
Meio Eletrônico: - .
Localização:BR191.1; 00687/s


  3 / 4 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:13827
Autor:Lal, Rup; Lal, Sukanya
Título:Recent trends in rifamycin research
..-
Fonte:s.l; s.n; 1994. 6 p. ilus.
Descritores:HANSENIASE
MYCOBACTERIUM AVIUM
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM TUBERCULOSIS
DNA POLIMERASE DIRIGIDO POR RNA
RIFAMICINAS
RIFAMICINAS
RIFAMICINAS
TUBERCULOSE
Localização:BR191.1; 06719/s


  4 / 4 HANSEN  
              first record previous record
seleciona
para imprimir
Id:8938
Autor:Fernandes, G.
Título:DDS X Rifampicina: comparacao da atividade terapeutica das duas drogas em gemeos hansenicos.
Descritores:HANSENIASE
HANSENIASE
HANSENIASE LEPROMATOSA
HANSENIASE LEPROMATOSA
HANSENIASE TUBERCULOIDE
HANSENIASE TUBERCULOIDE
SULFONAS
 SULFONAS
 SULFONAS
 SULFONAS
 SULFONAS
 RIFAMICINAS
 RIFAMICINAS
 RIFAMICINAS
 RIFAMICINAS
 RIFAMICINAS
 RIFAMICINAS
 RIFAMICINAS



página 1 de 1
   


Refinar a pesquisa
  Base de dados : HANSEN Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information